1Department of Veterinary Pathobiology, University of Minnesota, 1971 Commonwealth Ave, St Paul, MN 55108, USA. isaac015@umn.edu
Micrologix and Fujisawa are developing MBI-226, a gel formulation targeting bacterial infections. A Phase III trial began in 2000 to assess its efficacy in preventing catheter-related bloodstream infections.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: